As of January 2023
- Aesthetic
- Cell Therapy
- Diabetes & Metabolism
- Oncology & Immunology
- Vaccine
-
Preclinical (11)
-
LR20022
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Diabetes Modality NCE Target Undisclosed Partner - -
LR19131
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication NASH Modality NCE Target Undisclosed Partner - -
LR19020
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Obesity Modality NCE Target Undisclosed Partner - -
LR19025
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Osteoarthritis Modality Cell therapy Target Undisclosed Partner Medipost -
LR19023
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Oncology Modality Cell therapy Target Undisclosed Partner - -
LR22011
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Oncology Modality Cell therapy Target Undisclosed Partner -
-
LR20009
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Oncology Modality NCE Target Undisclosed Partner - -
LR19128
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Oncology Modality Biologics Target Undisclosed Partner Avactar Life sciences Affimer® Technology
-
LR19155
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication Oncology Modality Biologics Target Undisclosed Partner - -
LR20008
해당 프로젝트 팝업 Molecule - Stage Preclinical Indication HA filler Modality HA Target HA Partner - -
LR20062
해당 프로젝트 팝업 Molecule aP vaccine Stage Preclinical Indication aP vaccine Modality Vaccine Target aP vaccine Partner -
-
-
Phase I (10)
-
LR19129
해당 프로젝트 팝업 Molecule CUE-102 Stage Phase 1
(by Partner)Location summary USA Indication Oncology Modality Biologics Target WT-1 Partner Cue Biopharma -
LR19127
해당 프로젝트 팝업 Molecule CUE-101 Stage Phase 1
(by Partner)Location summary USA Indication HNSCC Modality Biologics Target HPV Partner Cue Biopharma -
LR19125
해당 프로젝트 팝업 Molecule PDC*Lung Stage Phase 1
(by Partner)Location summary Europe Indication NSCLC Modality Cell therapy Target Cancer vaccine Partner PDC*line Pharma -
LR20011
해당 프로젝트 팝업 Molecule GEN-001 Stage Phase 1
(by Partner)Location summary USA Indication Solid tumor Modality Microbiome Target Microbiome Partner Genome & Company -
LR21004
해당 프로젝트 팝업 Molecule BLR21004 Stage Phase 1
(by Partner)Location summary Australia Indication Osteoarthritis Modality Gene therapy Target Nkx3.2/AAV Partner ICM -
LR19021
해당 프로젝트 팝업 Molecule LB54640 Stage Phase 1 Location summary USA Indication Genetic Obesity Modality NCE Target MC4R Partner - -
LR20056
해당 프로젝트 팝업 Molecule LG303174 Stage Phase 1 Location summary USA Indication NASH Modality NCE Target VAP-1 Partner TransThera -
LR19123
해당 프로젝트 팝업 Molecule LC542019 Stage Phase 1 Location summary USA Indication Diabetes Modality NCE Target GPR120 Partner - -
LR19018
해당 프로젝트 팝업 Molecule LG203003 Stage Phase 1 Location summary USA Indication NASH Modality NCE Target DGAT-2 Partner - -
AV-380
해당 프로젝트 팝업 Molecule AV-380 Stage Phase 1 Location summary USA Indication Cachexia Modality Biologics Target VEGFR TKI Partner -
-
-
Phase II (4)
-
LR19114
해당 프로젝트 팝업 Molecule 6 in 1 Vaccine Stage Phase 2 Indication 6 in 1 Vaccine Modality Vaccine Target 6 in 1 Vaccine Partner - Diphtheriae (D), Bordetella pertussis (wP),
Clostridium tetani (T), Hepatitis B (HepB)
Haemophilus influenzae type b(Hib)
Vaccine-Associated Paralytic Poliomyelitis(IPV)
-
LR19019
해당 프로젝트 팝업 Molecule Zectivimod
Synonyms:LC510255Stage Phase 2 Location summary Republic of Korea
Partner: ChinaIndication Atopic dermatitis Modality NCE Target S1P1 Partner TransThera
(License-out)License-out, China
-
LR19024
해당 프로젝트 팝업 Molecule LG34053 Stage Phase 1b/2 Location summary Republic of Korea Indication Osteoarthritis Modality NCE Target Undisclosed Partner - -
AV-299
해당 프로젝트 팝업 Molecule Ficlatuzumab Stage Phase 2 Location summary USA Indication Head and neck squamous cell carcinoma Modality Biologics Target Anti-HGF/c-MET
IgG1 mAbPartner -
-
-
Phase III (5)
-
LR19074
해당 프로젝트 팝업 Molecule Tigulixostat
Synonyms:LC350189Stage Phase 3 Indication Gout Modality NCE Target XO
Xanthine OxidatePartner - -
LR20023
해당 프로젝트 팝업 Molecule Botulinum toxin Stage Phase 3 Location summary Republic of Korea Indication Botulinum toxin Modality Botulinum toxin Target Botulinum toxin Partner Pharma Research Bio -
LR19094
해당 프로젝트 팝업 Molecule Y-solution, China Stage Phase 3 Location summary China Indication HA filler Modality HA Target HA Partner - -
LR20024
해당 프로젝트 팝업 Molecule Y-solution, MDR Stage Phase 3 Location summary Europe Indication HA filler Modality HA Target HA Partner - -
AV-951
해당 프로젝트 팝업 Molecule Tivozanib Stage Phase 3 Location summary Global Indication Renal cell carcinoma Modality Biologics Target VEGFR TKI Partner Kyowa Kirin License-in Bristol Myers Squibb Opdivo combination
-
-
NDA (0)